Literature DB >> 24403581

MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Michael L Davies1, Janet J Sei, Nicholas A Siciliano, Ren-Huan Xu, Felicia Roscoe, Luis J Sigal, Laurence C Eisenlohr, Christopher C Norbury.   

Abstract

UNLABELLED: Although the pattern recognition receptor Toll-like receptor 2 (TLR2) is typically thought to recognize bacterial components, it has been described to alter the induction of both innate and adaptive immunity to a number of viruses, including vaccinia virus (VACV). However, many pathogens that reportedly encode TLR2 agonists may actually be artifactually contaminated during preparation, possibly with cellular debris or merely with molecules that sensitize cells to be activated by authentic TLR2 agonists. In both humans and mice, the most relevant natural route of infection with VACV is through intradermal infection of the skin. Therefore, we examined the requirement for TLR2 and its signaling adaptor MyD88 in protective immunity to VACV after intradermal infection. We find that although TLR2 may recognize virus preparations in vitro and have a minor role in preventing dissemination of VACV following systemic infection with large doses of virus, it is wholly disposable in both control of virus replication and induction of adaptive immunity following intradermal infection. In contrast, MyD88 is required for efficient induction of CD4 T cell and B cell responses and for local control of virus replication following intradermal infection. However, even MyD88 is not required to induce local inflammation, inflammatory cytokine production, or recruitment of cells that restrict virus from spreading systemically after peripheral infection. Thus, an effective antiviral response does require MyD88, but TLR2 is not required for control of a peripheral VACV infection. These findings emphasize the importance of studying relevant routes of infection when examining innate sensing mechanisms. IMPORTANCE: Vaccinia virus (VACV) provides the backbone for some of the most widely used and successful viral vaccine vectors and is also related to the human pathogens Cantagalo virus and molluscum contagiosum virus that infect the skin of patients. Therefore, it is vital to understand the mechanisms that induce a strong innate immune response to the virus following dermal infection. Here, we compare the ability of the innate sensing molecule Toll-like receptor 2 (TLR2) and the signaling molecule MyD88 to influence the innate and adaptive immune response to VACV following systemic or dermal infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24403581      PMCID: PMC3957935          DOI: 10.1128/JVI.02776-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  Innate immune recognition of poxviral vaccine vectors.

Authors:  Erin L Lousberg; Kerrilyn R Diener; Michael P Brown; John D Hayball
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

3.  Role of specific innate immune responses in herpes simplex virus infection of the central nervous system.

Authors:  Jennifer P Wang; Glennice N Bowen; Shenghua Zhou; Anna Cerny; An Zacharia; David M Knipe; Robert W Finberg; Evelyn A Kurt-Jones
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

4.  Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo.

Authors:  Eva Szomolanyi-Tsuda; Xueya Liang; Raymond M Welsh; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

Review 6.  TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity.

Authors:  Ulrich Zähringer; Buko Lindner; Seiichi Inamura; Holger Heine; Christian Alexander
Journal:  Immunobiology       Date:  2008-03-28       Impact factor: 3.144

7.  A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection.

Authors:  Michael Quigley; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

8.  Disruption of TNF-α/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection.

Authors:  Tian Tian; Krista Dubin; Qiushuang Jin; Ali Qureshi; Sandra L King; Luzheng Liu; Xiaodong Jiang; George F Murphy; Thomas S Kupper; Robert C Fuhlbrigge
Journal:  J Invest Dermatol       Date:  2012-02-09       Impact factor: 8.551

9.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  8 in total

1.  Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity.

Authors:  Ariana G Bravo Cruz; Aiguo Han; Edward J Roy; Arielle B Guzmán; Rita J Miller; Elizabeth A Driskell; William D O'Brien; Joanna L Shisler
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 2.  Molecular mechanisms of regulation of Toll-like receptor signaling.

Authors:  Cynthia A Leifer; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2016-06-24       Impact factor: 4.962

3.  IL-1R Type 1-Deficient Mice Demonstrate an Impaired Host Immune Response against Cutaneous Vaccinia Virus Infection.

Authors:  Tian Tian; Michelle Qiushuang Jin; Krista Dubin; Sandra L King; Wolfram Hoetzenecker; George F Murphy; Chen Amy Chen; Thomas S Kupper; Robert C Fuhlbrigge
Journal:  J Immunol       Date:  2017-05-03       Impact factor: 5.426

4.  A systemic macrophage response is required to contain a peripheral poxvirus infection.

Authors:  Michael L Davies; Nikhil J Parekh; Lauren W Kaminsky; Chetna Soni; Irene E Reider; Tracy E Krouse; Matthew A Fischer; Nico van Rooijen; Ziaur S M Rahman; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2017-06-14       Impact factor: 6.823

5.  Type I interferon-dependent CCL4 is induced by a cGAS/STING pathway that bypasses viral inhibition and protects infected tissue, independent of viral burden.

Authors:  Nikhil J Parekh; Tracy E Krouse; Irene E Reider; Ryan P Hobbs; Brian M Ward; Christopher C Norbury
Journal:  PLoS Pathog       Date:  2019-10-11       Impact factor: 6.823

6.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

Review 7.  Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development.

Authors:  Yongjun Sui; Jay A Berzofsky
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

Review 8.  Poxviral Targeting of Interferon Regulatory Factor Activation.

Authors:  Clara Lawler; Gareth Brady
Journal:  Viruses       Date:  2020-10-20       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.